A Win For Gamida Cell Ltd.

Fri, Jan 19, 2024 at 07:20 PM

Gamida Cell Ltd. (GMDA:NASDAQ) jumped higher at $0.3, representing a gain of 27%. The stock got featured on our News Catalysts scanner on Wed, Jan 17, 2024 at 10:28 AM in the 'MISCELLANEOUS' category. From Fri, Jan 05, 2024, the stock recorded 11.11% Up Days and 20.00% Green Days

The stock spiked on Fri, Dec 29, 2023 at $0.48 with a volume of 6M+.

About Gamida Cell Ltd. (GMDA:NASDAQ)

Gamida Cell Ltd is engaged in the development of cellular and immune therapeutics for cancer and rare genetic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy for use as a curative stem cell graft for patients in hematopoietic stem cell transplant. It is also developing NAM-NK, an innate immunotherapy of expanded natural killer cells, for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma.

Top 10 Gainers:

Vinco Ventures Inc. (BBIG:NASDAQ), 300%
Kaman Corporation (KAMN:NYSE), 100.85%
Mesa Air Group, Inc. (MESA:NASDAQ), 49.98%
Edgewise Therapeutics Inc. (EWTX:NASDAQ), 34.57%
Salem Media Group, Inc. (SALM:NASDAQ), 30.32%
Tricon Residential Inc. (TCN:NYSE), 28.27%
Gamida Cell Ltd. (GMDA:NASDAQ), 27.04%
ProMIS Neurosciences Inc. (PMN:NASDAQ), 27.01%
micromobility.com Inc Cl A (MCOM:NASDAQ), 26.9%
Palatin Technologies, Inc. (PTN:NYSEMKT), 26.03%